R&D Focusing too many R&D resources on one drug: The hidden cost... Drug development is a high-stakes, high-cost endeavour.
Events Partner Content 13th Annual Pharma Resource Planning and Portfolio Managemen... Prioritizing Projects with Tools, Data, and Governance
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
